The effect of interferon on the liver in chronic hepatitis C: A quantitative evaluation of histology by meta-analysis

Journal of Hepatology

Volumn 26, Issue 6, 1997, Pages 1187-1199

  Cammá, Calogero ^a   Giunta, Marco ^a   Linea, Cristina ^a   Pagliaro, Luigi ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Chronic hepatitis C; Interferon; Liver histology; Meta analysis

Indexed keywords

ALANINE AMINOTRANSFERASE; LYMPHOBLAST INTERFERON; RECOMBINANT ALPHA INTERFERON;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030740089     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80451-5     Document Type: Article

References (101)

1. Knodell RG, Ishak K, Black W, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
2. Scheuer PJ. Classification of chronic viral hepatitis: a need reassessment. J Hepatol. 13:1991;372-374.
3. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The hepatology of hepatitis C. Hepatology. 15:1992;567-571.
4. Ludiwig J. The nomenclature of chronic active hepatitis: an obituary. Gastroenterology. 105:1993;274-278.
5. Pagliaro L, Craxi A, Cammá C, Tinè F, Di Marco V, Lo Iacono O, Almasio P. Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology. 19:1994;820-828.
6. Ricahrd O, Glaumann H, Frydén A, Norkrans G, Schvarcz R, Sönnerborg A, Yun ZB, Weiland O. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology. 21:1995;918-922.
7. Mattsson L, Weiland O, Glaumann H. Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: clinical and histological outcome. Liver. 8:1988;184-188.
8. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HT. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology. 14:1991;969-974.
9. Wejstål R, Hermodsson S, Norkrans G. Long-term follow-up of chronic hepatitis non-A, non-B with special reference to hepatitis C. Liver. 11:1991;143-148.
10. Seeff LB, Buskell-Bales Z, Wrignt EC, et al. Long-term mortality after transfusion associated non-A, non-B hepatitis. N Engl J Med. 327:1992;1906-1911.
11. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol. 16:1992;273-281.
12. Koretz RL, Abbey H, Colemar E, Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med. 119:1993;110-115.
13. Mattsson L, Weiland O, Glaumann H. Chronic non-A, non-B hepatitis developed after transfusions, illicit self-injections or sporadically. Outcome during long-term follow-up - a comparison. Liver. 9:1989;120-127.
14. Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J. Randomized trial of lymphoblastoid α-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol. 17:1993;390-396.
15. Camps J, Garcia-Granero M, Riezu-Boj JI, Larrea E, De Alava E, Civeira MP, Castilla A, Prieto J. Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol. 21:1994;4-11.
16. Capra F, Casarii M, Gabrielli GB, Tognella P, Rizzi A, Dolci L, Colombari R, Mezzelani P, Corrocher R, De Sandre G. α-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers. J Hepatol. 18:1993;112-118.
17. Castilla A, Camps-Bansell J, Civeira MP, Prieto J. Lymphoblastoid α-interferon for chronic hepatitis C: a randomized controlled study. Am J Gastroenterol. 88:1993;233-239.
18. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, Fontanges T, Albrecht J, Meschievitz C, Trepo C. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 101:1991;497-502.
19. Craxi A, Di Marco V, Lo Iacono O, Almasio P, Bruno R, Cammà C, Volpes R, Pagliaro L. Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months. J Hepatol. 24:1996;539-546.
20. De Alava E, Camps J, Pardo-Mindán J, Garcia Granero M, Muñoz M, Sola J, Civeira MP, Contreras F, Vázquez JJ, Castilla A, Prieto J. Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alfa interferon. Liver. 13:1993;73-79.
21. Gallorini A, Plebani M, Pontisso P, Chemello L, Masiero M, Mantovani G, Alberti A. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2a interferon. Liver. 14:1994;125-164.
22. Gomez-Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreño V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant α-interferon in comparison with a control group. J Hepatol. 11:1990;S63-S67. (Suppl 1).
23. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kishida Y, Shiinizu Y, Inoue A, Fusamoto H, Kamada T. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology. 21:1995;297-297.
24. Lin R, Roach E, Zimmerman M, Strasser S, Arrel GC. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol. 23:1995;487-496.
25. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou JP. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 13:1991;393-397.
26. Mazzella G, Salzetta A, Casanova S, Morelli MC, Villanova N, Miniero R, Sottili S, Novelli V, Cipolla A, Festi D, Roda E. Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response. Dig Dis Sci. 39:1994;866-870.
27. Omata M, Ito Y, Yokosuka O, Imazeki F, Tagawa M, Takano S, Hosoda K, Tada M, Ohto M, Ito K, Okuda K. Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant α-interferon for chronic non-A, non-B hepatitis. Dig Dis Sci. 36:1991;1217-1222.
28. Richen J, Solioz M, Bühler H, Gonvers JJ, Knoblauch M, Lvanchy D, Malè PJ, Meyer B, Schmid M, Bianchi L. Low-dose interferon in chronic hepatitis non-A/non-B: effects on quantitative liver function and structure in a randomized, controlled multicenter trial. Clin Invest. 71:1993;888-893.
29. Rumi MG, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF. Long-term titrated recombinant interferon-α2a in chronic hepatitis C: a randomized controlled trial. J Viral Hep. 2:1995;73-76.
30. Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, Carreño V. High doses of recombinant α-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology. 13:1991;327-331.
31. Sieck JO, Ellis ME, Alfurayh O, Ali MA, Ali HA, Ayub A, Al Fadda M, Zafar M, Halim M, Bernvil SS, Saour J, Al Hokail A, Abate ML. Histologically advanced chronic hepatitis C treated with recombinant alpha-interferon: a randomized placebo-controlled double-blind cross-over study. J Hepatol. 19:1993;418-423.
32. Bresci G, Del Corso L, Romanelli AM, Giuliano G, Pentimone F. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis. J Am Geriatr Soc. 41:1993;857-862.
33. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P, Benvegnù L, Casarin C, Alberti A, Donada C, Cellini A, Cavinato F, D'Aquino M, Poozzato G, Terpin M, Urban F, Da Broi G, Macor C, Brosolo P, Pristerà G. Randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. Hepatology. 22:1995;700-706.
34. Cimino L, Nardone G, Citarella C, Perna E, Capuano G, Budillon G. Treatment of chronic hepatitis C with recombiannt interferon alfa. Ital J Gastroenterol. 23:1991;399-402.
35. David E, Pucci A, Palladin D, Saracco G, Garello E, Pintus C, Rocca G, Chiandussi L, Solinas A, Mollo F, Rizzetto M, Mazzucco G, Verme G. Histologic changes in liver biopsy specimens produced by recombinant interferon α-2b therapy for chronic non-A, non-B viral hepatitis: a randomized controlled trial. Am J Clin Pathol. 98:1992;397-401.
36. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HD Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JI, Van Thiel HD, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego T, Gibas A. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized controlled trial. N Engl J Med. 321:1989;1501-1506.
37. Di Besceglie A, Martin P, Kassianides C, Lisker Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 321:1989;1506-1510.
38. Diodati G, Bonetti P, Noventa F, Casarin C, Rugge M, Scaccabarozzi S, Tagger A, Pollice L, Tremolada F, Davite C, Realdi G, Ruol A. Treatment of chronic hepatitis C with recombinant human interferon-α 2a: results of a randomized controlled clinical trial. Hepatology. 19:1994;1-5.
39. Farrell G, Lin R, Schoeman M, Craig P, MacDonald J, Batey RG. Interferon alfa-2b for chronic active hepatitis C: interim results of an Australian trial. J Hepatol. 11:1990;S157. Suppl. 1.
40. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S. Randomized trial of effect of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 346:1995;1051-1055.
41. Pérez R, Pravia R, Linares A, González M, Rodriguez M, Lombraña JLS, Riestra S, Suárez A, Rodrigo E. Treatment of chronic hepatitis C with recombinant interferon alfa-2b for nine months. Gut. 34:1993;S136-S138. Suppl.
42. Picciotto A, Varagona G, Valle F, Coviello DA, Lapertosa G, Celle G. Interferon therapy in chronic hepatitis C. Evaluation of a low dose maintenance schedule in responder patients. J Hepatol. 17:1993;359-363.
43. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Conzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 332:1995;1457-1462.
44. Realdi G, Diodati G, Bonetti P, Scaccabarozzi S, Alberti A, Ruol A. Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial. J Hepatol. 11:1990;S68-S71. Suppl 1.
45. Saracco G, Rosina F, Torrani Cerenzia MR, Lattore V, Chiandussi L, Gallo V, Petrino R, De Micheli AG, Donegani E, Solinas A, Deplano A, Tocco A, Cossu P, Pintus C, David E, Mazzucco G, Verme G, Rizzetto M. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol. 11:1990;S43-S49. Suppl 1.
46. Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstål R, Frydén A. Interferon alpha-2b treatment of chronic post-transfusion non-A non-B/C hepatitis: long-term outcome and effect of increase interferon doses in non-responders. Scand J Infect Dis. 23:1991;413-420.
47. Valla D, Babany G, Ouzan D, Trépo C, Bourliére M, Calés P, Payen JL, Couzigou P, Buffet C, Michel P, Veyrac M, Bercoff E, Lévy VG, Paris JC, Grangé JD, Valla A, Fischer D, Eugéne C, Denis J, Voigt JJ, Fabre M, Le Charpentier Y, Opolon P. Prevention of relapse in patients with chronic non-A, non-B/C hepatitis who respond to alpha-interferon. A controlled multicenter trial of low-dose maintenance therapy. J Hepatol. 21:1994;774-778.
48. Varagona G, Kibbler H, Smith M, Sherlock S, Dusheiko G. A phase II study of interferon alfa-2b treatment of anti-HCV positive and negative chronic NANB hepatitis: interim analysis. J Hepatol. 11:1990;S165. Suppl 1.
49. Angelini G, Sgarbi D, Colombari R, Bezi A, Castagnini A, De Berardinis F, Conti A, Di Piramo D, Dolci L, Falezza G, Geccherle A, Gottardi S, Martella F, Mostacci R, Piubello W, Tafner G, Tomba A, Rigo L. Alpha-interferon treatment of chronic hepatitis C: a controlled, multicentre, prospective study. Digestion. 56:1995;199-203.
50. Bjøro K, Krarup H, Bell P, Christophersen S, Evensen S, Frøland S, Laursen A, Lippe v.d. B, Maeland A, Ranrk L, Ring-Larsen H, Schou G, Schrumpf E, Tygstrup N. Two dose regimes of recombinant interferon-alpha-2b in chronic hepatitis C virus infection. Scand J Gastroenterol. 30:1995;119-124.
51. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trial. N Engl J Med. 316:1987;450-455.
52. Weiland O, Schvarcz R, Wejstål R, Norkrans G, Frydén A. Therapy of chronic posttransfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience. J Hepatol. 11:1990;S57-S62. Suppl 1.
53. Bonetti P, Diodati G, Scaccabarozzi S, Realdi G, Tagger A, Alberti A, Ruol A. Treatment of cryptogenic chronic liver diseases with recombinant alpha-2a interferon. Preliminary results of a randomized controlled clinical trial. Ann Ital Med Int. 5:1990;169-173.
54. Giudici-Cipriani A, Rainisio C, Ponassi I, Rattenni S, Imberciadori G, Cavagnaro G, Marenco G. Therapy of chronic non-A, non-B hepatitis with interferon alfa-2B. A controlled clinical study and long-term follow-up. Minerva Gastroenterol Dietol. 37:1991;85-90.
55. Liaw F, Sheen IS. Randomized controlled trial of recombinant interferon alfa-2b in chronic NANB hepatitis: dose schedules and results. J Hepatol. 11:1990;S160. Suppl 1.
56. Farrell GC, Lin R, Coverdale S. Prediction of response to interferon in patients with chronic active hepatitis C, and evidence that this improves hepatic metabolic function. Gastroenterol Jpn. 26:1991;243-246. Suppl 3.
57. Makris M, Preston FE, Triger DR, Underwood JCE, Westlake L, Adelman MI. A randomized controlled trial of recombinant interferon-α in chronic hepatitis C in hemophiliacs. Blood. 78:1991;1672-1677.
58. Shindo M, Di Bisceglie AM, Cheung L, Shih JWK, Cristiano K, Feinstone SM, Hoofnagle JH. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 115:1991;700-704.
59. Diodati G, Bonetti P, Tagger A, Alberti A, Realdi G, Ruol A. Interferon therapy of cryptogenic chronic active liver disease and its relationship to anti-HCV. Arch Virol. 1992;299-303. Suppl 4.
60. Picciotto A, Varagona G, Valle F, Coviello DA, Lapertosa G, Celle G. Interferon therapy in chronic hepatitis C. Evaluation of a low-dose maintenance schedule in responder patients. J Hepatol. 17:1993;359-363.
61. Iino S. High dose interferon treatment in chronic hepatitis C. Gut. 34:1993;S114-S118. Suppl.
62. Yatsuhashi H, Inoue O, Inokuchi K, Koga M, Nagataki S, Cha TA, Irvine B, Stempien M, Kolberg J, Urdea MS, Yano M. Short and long-term effects of interferon on serum markers of hepatitis C virus replication. J Gastroenterol Hep. 8:1993;1-6.
63. Solinas A, Cossu P, Poddighe P, Tocco A, Deplano A, Garrucciu G, Diana MS. Changes of serum 2′,5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C. Liver. 13:1993;253-258.
64. Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology. 105:1993;507-512.
65. Makris M, Preston FE, Triger DR, Underwood JCE, Westlake L, Adelman MI. Interferon alfa for chronic hepatitis C in haemophiliacs. Gut. 34:1993;S121-S123. Suppl.
66. Zielinska W, Paszkiewicz J, Korczak A, Wlasiuk M, Zoltowska A, Szutowicz A, Cummins JM, Georgiades JA. Treatment of six patients with chronic active HCV hepatitis, with low dose natural human interferon alpha administered orally. Arch Immunol Ther Exp Warsz. 41:1993;253-257.
67. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JB. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther. 16:1994;334-343.
68. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology. 107:1994;812-817.
69. Watson AR, Bartlome P. High-dose interferon alfa-2A for the treatment of chronic hepatitis C. Ann Pharmacother. 28:1994;341-342.
70. Hopf U, Kuther S, Konig V, Heuft HG, Berg T, Huhn D. Current status of treatment for chronic viral hepatitis using recombinant interferon alpha. Dtsch Med Wochenschr. 119:1994;961-964.
71. Chayama K, Arasa Y, Koida I, Tsubota A, Saitoh S, Ikeda K, Matsumoto T, Kanda M, Iwasaki S, Kobayashi M, Hashimoto M, Unakami M, Morinaga T, Kumada H. Anti-viral effect of lymphoblastoid interferon-alpha on hepatitis C virus in patients with chronic hepatitis type C. J Gastroenterol Hep. 9:1994;128-133.
72. Boucher E, Jouanolle H, Andre P, Ruffault A, Guyader D, Moirand R, Turlin B, Jacquelinet C, Brissot P, Deugnier Y. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: result from controlled randomized trial in 80 patients. Hepatology. 21:1995;322-327.
73. Angelico M, Gandin C, Pescarmona E, Rapicetta M, Del Vecchio C, Bini A, Spada E, Baroni L. Recombinant interferon-α and ursodeoxycholic acid versus interferon-α alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am J Gastroenterol. 90:1995;263-269.
74. Hopf U, Moller B, Konig V, Kuther S, Lobeck H, Huhn D. Long-term treatment of cryptogenic hepatitis C using recombinant interferon alpha. Z Gastroenterol. 28:1990;453-457.
75. Jacyna MR, Brooks MG, Loke RHI, Main J, Murrai-Lyon MI, Thomas HC. A controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis. Br Med J. 298:1989;80-82.
76. Kakumu S, Arao M, Yoshioka K, Hayashi H, Kusakabe A, Hirofuji H, Kawabe M. Recombinant human-interferon therapy for chronic non-A, non-B hepatitis: second report. Am J Gastroenterol. 85:1990;655-659.
77. Lin R, Grierson J, Schoeman MN, McDonald JA, Craig PI, Batey RG, Bilous M, Farrell GC. Can the response to interferon treatment be predicted in patients with chronic active hepatitis C? Aust NZ J Med. 21:1991;387-392.
78. Terranova R, Luca S. Treatment of chronic hepatitis C with recombinant interferon alpha 2b. J Chemother. 4:1992;297-302.
79. Wejstål R, Norkrans G, Lenkei R, Weiland O, Schvarcz R, Frydén A. Peripheral blood lymphocyte subset in patients with chronic hepatitis C - effect of interferon treatment. Liver. 12:1992;162-167.
80. Alberti A, Chemello L, Bonetti P, Casarin C, Diodati G, Cavalletto L, Cavalletto D, Frezza M, Donada C, Belussi F, Casarin P, Pozzato G, Ruol A. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. J Hepatol. 17:1983;. S123-S126.
81. Benelux multicentre trial of alpha interferon treatment for chronic hepatitis C: standard v high dose treatment monitored by biochemical and virological markers (interim analysis). Gut. 34:1993;S119-S120. Suppl.
82. Caporaso N, Suozzo R, Morisco F, D'Antonio M, Romano M, Coltorti M. Recombinant human interferon alfa-2a therapy of chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year. Ital J Gastroenterol. 25:1993;482-486.
83. De Bac C, Grimaldi F, Clementi C, Duca F, Livoli D, Taliani G. Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C. Gut. 34:1993;S135. Suppl.
84. Douglas DD, Rakela J, Lin HJ, Holinger FB, Taswell HF, Czaja AJ, Gross JB, Anderson ML, Parent K, Fleming CR, Cangemi JR, O'Brien PC, Powis PK. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C: comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Dig Dis Sci. 38:1993;601-607.
85. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology. 104:1993;877-883.
86. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with hig-dose interferon a-2b: a multicenter study. Dig Dis Sci. 38:1193;612-618.
87. Kagawa T, Morizane T, Saito H, Miyaguchi S, Tsunematsu S, Tada S, Guevara FM, Kumagai N, Tsuchimoto K, Watanabe T, Tsuchiya M. A randomized controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C. J Hepatol. 17:1993;91-96.
88. Kleter GEM, Brouwer JT, Heijtink RA, Schalm SW, Quint WGV. Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon. Antimicrob Agents Chemother. 37:1993;595-597.
89. Metreau IM. . for the study of NANB/C chronic hepatitis treatment Gut. 1993;S112-S113. Suppl.
90. Attili AF, Natali L, Onori L, Festuccia V, Natali GF. Treatment of type C chronic active hepatitis with interferon-α-2a: treatment duration does not influence biochemical remission but does decrease the relapse rate. J Clin Gastroenterol. 19:1994;214-216.
91. Budillon G, Cimino L, Del Vecchio Blanco C, Mazzacca G, Iaquinto G, D'Ascoli B, Lampasi F, Sapio D, Matera D, Ambrogio G, Ambrosone L. Long-term follow-up evaluation in HCV chronic hepatitis treated with alpha-2b interferon. A comparison of two protocols. Ital J Gastroenterol. 26:1994;16-20.
92. Jouët P, Roudot-Thoraval F, Dhumeaux D, Métreau JM. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology. 106:1994;686-690.
93. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon-α2a therapy in patients with chronic hepatitis C. Dig Dis Sci. 39:1994;1273-1280.
94. Negro F, Baldi M, Mondardini A, Leandro G, Chaneac M, Manzini P, Abate ML, Zahm F, Dastoli G, Ballar M, Ryff JC, Verme G, Bonino F. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology. 107:1994;479-485.
95. Saito T, Shinzawa H, Kuboki M, Ishibashi M, Toda H, Okuyama Y, Nakamura T, Yamada N, Wakabayashi H, Togashi H, Takahashi T. A randomized controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol. 89:1994;681-685.
96. Marcellin P, Povteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, Lemonnier C, Degott C, Erlinger S, Benhamou JP. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology. 109:1995;156-165.
97. Yokosuka O, Kato N, Hosoda K, Ito Y, Imazeki F, Ohto M, Omata M. Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA. Gut. 37:1995;721-726.
98. Shadish WR, Haddock CK. Combining estimates of effect size. Cooper H, Hedges LV. The Handbook of Research Synthesis. 1994;261-281 Russel Sage Foundation, New York.
99. Fleiss JL. Statistical Methods for Rates and Proportions. 1981;John Wiley, New York.
100. SAS Guide for Personal Computers. 1988;SAS Institute Inc, Cary, NC. Version 6.03.
101. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 20:1994;15-20.